Polymeric nanoparticles as therapeutic agents against coronavirus disease
Source abstract
Abstract
Nanotechnology has the potential to improve the combat against life-threatening conditions. Considering the COVID-19 scenario, and future outbreaks, nanotechnology can play a pivotal role in several steps, ranging from disinfection protocols, manufacture of hospital clothes, to implementation of healthcare settings. Polymeric nanoparticles are colloidal particles with size ranging from 10 to 999 nm, composed of natural or synthetic polymers. The versatility of polymeric-based nanoparticle engineering can provide (i) specificity, (ii) tunable release kinetics, and (iii) multimodal drug composition, making it possible to overcome common limitations encountered during traditional drug development. Consequently, these particles have been widely used as drug delivery systems against several diseases, such as cancer. Due to inherent competitive advantages, polymeric-based nanoparticles hold astonishing potential to counteract the new coronavirus disease (COVID-19). For this reason, in the present study, the latest advancements in polymer-based nanotechnology approaches used to fight against SARS-CoV-2 are compiled and discussed. Moreover, the importance of forefront in vitro technologies - such as 3D bioprinting and organ-on-chip - to evaluate the efficacy of nanotherapeutic agents is also highlighted. Polymeric nanoparticles can be functionalized to enhance its potential as a nanotherapeutic agent. Due to its many advantages, polymeric-based nanoparticles systems are a promising approach against coronavirus disease 2019 (COVID-19).
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · 3D Printing in Biomedical Research · COVID-19 diagnosis using AI
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (85)
Show source-provided references
1. Abo-zeid Y, Williams GR, Touabi L, McLean GR (2020) An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles. Int J Pharm. 589:11982610.1016/j.ijpharm.2020.119826 ↗
2. Aleissa MM, Silverman EA, Paredes Acosta LM, Nutt CT, Richterman A, Marty FM (2021) New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrob Agents Chemother 6510.1128/AAC.01814-20 ↗
3. Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D (2019) Nanoparticle-based vaccines against respiratory viruses. Front Immunol 10:1–1110.3389/fimmu.2019.00022 ↗
4. Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: an update. Bioeng Transl Med 410.1002/btm2.10143 ↗
5. Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 71:1185–119810.1111/jphp.13098 ↗
6. Aziz A, Geng C, Fu M, Yu X, Qin K, Liu B (2017) The role of microfluidics for organ on chip simulations. Bioengineering 4:3910.3390/bioengineering4020039 ↗
7. Bandopadhyay S, Manchanda S, Chandra A, Ali J, Deb PK (2019) Overview of different carrier systems for advanced drug delivery. Elsevier Inc.10.1016/B978-0-12-814487-9.00005-3 ↗
8. Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R (2020) Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater 108:1–2110.1016/j.actbio.2020.03.020 ↗
9. Bhise NS, Manoharan V, Massa S, Tamayol A, Ghaderi M, Miscuglio M et al (2016) A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 8:01410110.1088/1758-5090/8/1/014101 ↗
10. Chan LJ, Feeney OM, Leong NJ, McLeod VM, Porter CJH, Williams CC et al (2017) An evaluation of optimal PEGylation strategies for maximizing the lymphatic exposure and antiviral activity of interferon after subcutaneous administration. Biomacromol 18:2866–287510.1021/acs.biomac.7b00794 ↗
11. Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO (2020) Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano 14:7760–778210.1021/acsnano.0c04006 ↗
12. Cong Y, Han X, Wang Y, Chen Z, Lu Y, Liu T et al (2020) Drug toxicity evaluation based on organ-on-a-chip technology: a review. Micromachines 11:38110.3390/mi11040381 ↗
13. Da Silva AL, Santos RS, Xisto DG, Alonso SDV, Morales MM, Rocco PRM (2013) Nanoparticle-based therapy for respiratory diseases. An Acad Bras Cienc 85:137–14610.1590/S0001-37652013005000018 ↗
14. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N et al (2020) Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int J Environ Res Public Health 17:269010.3390/ijerph17082690 ↗
15. Drobysh M, Ramanaviciene A, Viter R, Ramanavicius A (2021) Affinity sensors for the diagnosis of covid-19. Micromachines 12:1–1910.3390/mi12040390 ↗
16. Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B et al (2020) The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother 75:3366–337210.1093/jac/dkaa331 ↗
17. FDA approves first treatment for COVID-19. FDA Website 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (accessed April 13, 2021).
18. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D (2021) SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 397:952–95410.1016/S0140-6736(21)00370-6 ↗
19. Forni G, Mantovani A (2021) COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28:626–63910.1038/s41418-020-00720-9 ↗
20. Gao D, Guo X, Zhang X, Chen S, Wang Y, Chen T, et al (2020) Multifunctional phototheranostic nanomedicine for cancer imaging and treatment. vol. 5. Elsevier Ltd10.1016/j.mtbio.2019.100035 ↗
21. Gorle AP, Gattani SG (2009) Design and evaluation of polymeric ocular drug delivery system. Chem Pharm Bull (tokyo) 57:914–91910.1248/cpb.57.914 ↗
22. Gref R, Minamitake Y, Peracchia M, Trubetskoy V, Torchilin V, Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600–160310.1126/science.8128245 ↗
23. Grigoryan B, Paulsen SJ, Corbett DC, Sazer DW, Fortin CL, Zaita AJ et al (2019) Multivascular networks and functional intravascular topologies within biocompatible hydrogels. Science 364:458–46410.1126/science.aav9750 ↗
24. Homan KA, Kolesky DB, Skylar-Scott MA, Herrmann J, Obuobi H, Moisan A et al (2016) Bioprinting of 3D convoluted renal proximal tubules on perfusable chips. Sci Rep 6:3484510.1038/srep34845 ↗
25. Islam MR, Hoque MN, Rahman MS, Alam ASMRU, Akther M, Puspo JA et al (2020) Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity. Sci Rep 10:1400410.1038/s41598-020-70812-6 ↗
26. Jagaran K, Singh M (2020) Nanomedicine for covid-19: potential of copper nanoparticles. Biointerface Res Appl Chem 11:10716–1072810.33263/BRIAC113.1071610728 ↗
27. Jain A, Kumari R, Tiwari A, Verma A, Tripathi A, Shrivastava A et al (2018) Nanocarrier based advances in drug delivery to tumor: an overview. Curr Drug Targets 19:1498–151810.2174/1389450119666180131105822 ↗
28. Jazayeri MH, Amani H, Pourfatollah AA, Pazoki-Toroudi H, Sedighimoghaddam B (2016) Various methods of gold nanoparticles (GNPs) conjugation to antibodies. Sens Bio-Sensing Res 9:17–2210.1016/j.sbsr.2016.04.002 ↗
29. Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 8:e46–e4710.1016/S2213-2600(20)30216-2 ↗
30. Kalyane D, Maheshwari R, Raval N, Chauhan AS, Tekade RK (2018) Transportation and biointeraction properties in nanomaterials across biological systems. Elsevier Inc.10.1016/B978-0-12-817909-3.00009-1 ↗
31. Khoris IM, Ganganboina AB, Suzuki T, Park EY (2021) Self-assembled chromogen-loaded polymeric cocoon for respiratory virus detection. Nanoscale 13:388–39610.1039/D0NR06893D ↗
32. Kim MG, Park JY, Shon Y, Kim G, Shim G, Oh YK (2014) Nanotechnology and vaccine development. Asian J Pharm Sci 9:227–23510.1016/j.ajps.2014.06.002 ↗
33. Kulterer MR, Reischl M, Reichel VE, Hribernik S, Wu M, Köstler S et al (2011) Nanoprecipitation of cellulose acetate using solvent/nonsolvent mixtures as dispersive media. Colloids Surfaces A Physicochem Eng Asp 375:23–2910.1016/j.colsurfa.2010.11.029 ↗
34. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surfaces B Biointerfaces 75:1–1810.1016/j.colsurfb.2009.09.001 ↗
35. Li B, Wang W, Song W, Zhao Z, Tan Q, Zhao Z et al (2021) Antiviral and anti-inflammatory treatment with multifunctional alveolar macrophage-like nanoparticles in a surrogate mouse model of COVID-19. Adv Sci 2003556:1–14
36. Ma J, Wang Y, Liu J (2018a) Bioprinting of 3D tissues/organs combined with microfluidics. RSC Adv 8:21712–2172710.1039/C8RA03022G ↗
37. Ma X, Liu J, Zhu W, Tang M, Lawrence N, Yu C et al (2018b) 3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling. Adv Drug Deliv Rev 132:235–25110.1016/j.addr.2018.06.011 ↗
38. Manchanda S, Das N, Chandra A, Bandyopadhyay S, Chaurasia S (2019) Fabrication of advanced parenteral drug-delivery systems. Elsevier Inc.; 201910.1016/B978-0-12-814487-9.00002-8 ↗
39. Manek E, Petroianu GA (2020) Brain delivery of antidotes by polymeric nanoparticles. J Appl Toxicol 1–1310.1002/jat.4029 ↗
40. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N (2009) Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 260:33–3810.1016/j.cellimm.2009.07.004 ↗
41. Medhi R, Srinoi P, Ngo N, Tran HV, Lee TR (2020) Nanoparticle-based strategies to combat COVID-19. ACS Appl Nano Mater 3:8557–858010.1021/acsanm.0c01978 ↗
42. Milane L, Amiji M (2021) Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv Transl Res10.1007/s13346-021-00911-y ↗
43. Militky J, Novak O, Kremenakova D, Wiener J, Venkataraman M, Zhu G et al (2021) A review of impact of textile research on protective face masks. Materials (basel) 14:1–1610.3390/ma14081937 ↗
44. Montanheiro TL do A, Ribas RG, Montagna LS, de Menezes BRC, Schatkoski VM, Rodrigues KF et al (2020) A brief review concerning the latest advances in the influence of nanoparticle reinforcement into polymeric-matrix biomaterials. J Biomater Sci Polym Ed. 31:1869–9310.1080/09205063.2020.1781527 ↗
45. Mousavizadeh L, Ghasemi S (2020) Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect10.1016/j.jmii.2020.03.022 ↗
46. Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol. 2020;15:963.10.1038/s41565-020-00820-0 ↗
47. Neufurth M, Wang X, Tolba E, Lieberwirth I, Wang S, Schröder HC et al (2020) The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. Biochem Pharmacol. 182:11421510.1016/j.bcp.2020.114215 ↗
48. Neufurth M, Wang X, Wang S, Schröder HC, Müller WEG (2021) Caged dexamethasone/quercetin nanoparticles, formed of the morphogenetic active inorganic polyphosphate, are strong inducers of MUC5AC. Mar Drugs 19:6410.3390/md19020064 ↗
49. Novak R, Didier M, Calamari E, Ng CF, Choe Y, Clauson SL, et al (2018) Scalable fabrication of stretchable, dual channel, microfluidic organ chips. J Vis Exp10.3791/58151 ↗
50. Oleaga C, Bernabini C, Smith AST, Srinivasan B, Jackson M, McLamb W et al (2016) Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep 6:2003010.1038/srep20030 ↗
51. Organization WH. WHO coronavirus (COVID-19) dashboard n.d. https://covid19.who.int/ (accessed May 10, 2021).10.46945/bpj.10.1.03.01 ↗
52. Park JY, Jang J, Kang H-W (2018) 3D Bioprinting and its application to organ-on-a-chip. Microelectron Eng 200:1–1110.1016/j.mee.2018.08.004 ↗
53. Parvez MK, Parveen S (2017) Evolution and emergence of pathogenic viruses: past, present, and future. Intervirology 60:1–710.1159/000478729 ↗
54. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M del P, Acosta-Torres LS et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 16:7110.1186/s12951-018-0392-8 ↗
55. Peng W, Datta P, Ayan B, Ozbolat V, Sosnoski D, Ozbolat IT (2017) 3D bioprinting for drug discovery and development in pharmaceutics. Acta Biomater 57:26–4610.1016/j.actbio.2017.05.025 ↗
56. Pinto MCC, Cipolatti EP, Manoel EA, Freire DMG, Becer ÇR, Pinto JC (2020) Production of new functionalized polymer nanoparticles and use for manufacture of novel nanobiocatalysts. Macromol Mater Eng 305:200006510.1002/mame.202000065 ↗
57. Pooladanda V, Thatikonda S, Godugu C (2020) The current understanding and potential therapeutic options to combat COVID-19. Life Sci. 254:11776510.1016/j.lfs.2020.117765 ↗
58. Rahmani H, Davoudi-Monfared E, Nourian A, Nabiee M, Sadeghi S, Khalili H et al (2020) Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. DARU, J Pharm Sci 28:625–63410.1007/s40199-020-00369-2 ↗
59. Rana MM (2021) Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. J Biomater Sci Polym Ed 32:1219–124910.1080/09205063.2021.1909412 ↗
60. Rezvantalab S, Drude NI, Moraveji MK, Güvener N, Koons EK, Shi Y et al (2018) PLGA-based nanoparticles in cancer treatment. Front Pharmacol 9:1–1910.3389/fphar.2018.01260 ↗
61. Ruiz-Hitzky E, Darder M, Wicklein B, Ruiz-Garcia C, Martín-Sampedro R, del Real G et al (2020) Nanotechnology Responses to COVID-19. Adv Healthc Mater 9:1–2610.1002/adhm.202000979 ↗
62. Sahandi Zangabad P, Karimi M, Mehdizadeh F, Malekzad H, Ghasemi A, Bahrami S et al (2017) Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger. Nanoscale. 9:1356–9210.1039/C6NR07315H ↗
63. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP (2010) Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 385:143–14910.1016/j.ijpharm.2009.10.004 ↗
64. Siewert CD, Haas H, Cornet V, Nogueira SS, Nawroth T, Uebbing L et al (2020) Hybrid biopolymer and lipid nanoparticles with improved transfection efficacy for mRNA. Cells 9:1–1910.3390/cells9092034 ↗
65. Singh AK, Mishra G, Maurya A, Kulkarni GT, Awasthi R (2020) Biofabrication: an interesting tool to create in vitro model for COVID-19 drug targets. Med Hypotheses. 144:11005910.1016/j.mehy.2020.110059 ↗
66. Skardal A, Devarasetty M, Forsythe S, Atala A, Soker S (2016) A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol Bioeng 113:2020–203210.1002/bit.25950 ↗
67. Sun R, Luo Q, Wang Y, Chu H, Li X, Shen Z et al (2021) Supramolecular engineering of polymeric nanodrugs for antitumor chemotherapy. Chem Eng J. 416:12796810.1016/j.cej.2020.127968 ↗
68. Sur S, Rathore A, Dave V, Reddy KR, Chouhan RS, Sadhu V (2019) Recent developments in functionalized polymer nanoparticles for efficient drug delivery system. Nano-Structures & Nano-Objects 20:10039710.1016/j.nanoso.2019.100397 ↗
69. Tay A, Pavesi A, Yazdi SR, Lim CT, Warkiani ME (2016) Advances in microfluidics in combating infectious diseases. Biotechnol Adv 34:404–42110.1016/j.biotechadv.2016.02.002 ↗
70. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M et al (2020) Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 33:1007–101410.1038/s41379-020-0536-x ↗
71. Trampe E, Koren K, Akkineni AR, Senwitz C, Krujatz F, Lode A et al (2018) Functionalized bioink with optical sensor nanoparticles for O2 imaging in 3D-bioprinted constructs. Adv Funct Mater 28:180441110.1002/adfm.201804411 ↗
72. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC et al (2020) Diagnosing COVID-19: the disease and tools for detection. ACS Nano 14:3822–383510.1021/acsnano.0c02624 ↗
73. Veronese FM, Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs 22:315–32910.2165/00063030-200822050-00004 ↗
74. Wang G, Yang L, Li C, Yu H, He Z, Yang C et al (2021) Novel strategy to prepare fluorescent polymeric nanoparticles based on aggregation-induced emission: via precipitation polymerization for fluorescent lateral flow assay. Mater Chem Front 5:2452–245810.1039/D0QM00998A ↗
75. Wang H, Zhou Y, Sun Q, Zhou C, Hu S, Lenahan C, et al (2021) Update on nanoparticle-based drug delivery system for anti-inflammatory treatment. Front Bioeng Biotechnol 910.3389/fbioe.2021.630352 ↗
76. Weiss C, Carriere M, Fusco L, Capua I, Regla-Nava JA, Pasquali M et al (2020) Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano 14:6383–640610.1021/acsnano.0c03697 ↗
77. Witika BA, Makoni PA, Mweetwa LL, Ntemi PV, Chikukwa MTR, Matafwali SK et al (2020) Nano-biomimetic drug delivery vehicles: potential approaches for COVID-19 treatment. Molecules 25:1–2010.3390/molecules25245952 ↗
78. Wu J, Wang H, Li B (2020) Structure-aided ACEI-capped remdesivir-loaded novel PLGA nanoparticles: toward a computational simulation design for anti-SARS-CoV-2 therapy. Phys Chem Chem Phys 22:28434–2843910.1039/D0CP04389C ↗
79. Yang D (2021) Application of nanotechnology in the COVID-19 pandemic. Int J Nanomedicine 16:623–64910.2147/IJN.S296383 ↗
80. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O (2020) Therapeutic nanoparticles and their targeted delivery applications. Molecules 25:219310.3390/molecules25092193 ↗
81. Zhang M, Hong Y, Chen W, Wang C (2017) Polymers for DNA vaccine delivery. ACS Biomater Sci Eng 3:108–12510.1021/acsbiomaterials.6b00418 ↗
82. Zhang B, Korolj A, Lai BFL, Radisic M (2018) Advances in organ-on-a-chip engineering. Nat Rev Mater 3:257–27810.1038/s41578-018-0034-7 ↗
83. Zhang Q, Honko A, Zhou J, Gong H, Downs SN, Vasquez JH et al (2020) Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett 20:5570–557410.1021/acs.nanolett.0c02278 ↗
84. Zheng F, Fu F, Cheng Y, Wang C, Zhao Y, Gu Z (2016) Organ-on-a-chip systems: microengineering to biomimic living systems. Small 12:2253–228210.1002/smll.201503208 ↗
85. Zhou J, Kroll AV, Holay M, Fang RH, Zhang L (2020) Biomimetic nanotechnology toward personalized vaccines. Adv Mater 32:190125510.1002/adma.201901255 ↗